INTRODUCTION
Elevated resting heart rate (HR) increases the morbidity and mortality of patients with chronic systolic heart failure (CHF) [1, 2] or coronary artery disease with left ventricular systolic dysfunction [3] . Furthermore, there is substantial evidence that reduction in elevated HR improves the outcome of patients with cardiovascular diseases [4, 5] . Beta-blockers are the primary pharmacological option available to lower HR. They reduce left ventricular load, suppress the adrenergic stimulus, improve myocardial remodeling, and thereby reduce cardiovascular morbidity and mortality [6] .
Therefore, beta-blocking agents have been recommended for many years in international guidelines as a standard therapy in CHF [7] .
However, many patients on beta-blocker therapy, even if optimized, still present with elevated HR [8, 9] . Other patients have contraindications or cannot be treated with beta-blockers due to intolerable side effects. For several years, ivabradine has been available as an alternative HR-reducing agent. It reduces HR by selectively blocking the ''funny'' cardiac pacemaker current (I f ) channel in the pacemaker cells in the sinoatrial node. In patients with chronic stable angina pectoris, ivabradine has an anti-ischemic and antianginal effect comparable to that of betablockers [10] and calcium channel blockers [11] .
Furthermore, the SHIFT study (Systolic Heart faIlure treatment with the I f inhibitor ivabradine Trial; #ISRCTN70429960)
demonstrated that ivabradine also improved the cardiovascular outcome of CHF patients with an elevated HR (C70 bpm) compared with placebo [12] . The risk for the composite primary end point (cardiovascular death and hospital admission for worsening heart failure) was significantly reduced by 18%. Interestingly, this risk reduction was achieved on top of background pharmacotherapy, including betablockers, recommended by heart failure guidelines. A sub-analysis of SHIFT found that patients with an initial HR C75 bpm gained a significant benefit from ivabradine compared with placebo in all pre-specified end points, including risk of total mortality, CHF-associated mortality, and hospital admission due to worsening heart failure [13] .
Consequently, the European Medicines Agency approved ivabradine for CHF patients in New York Heart Association (NYHA) classes II to IV with reduced left ventricular ejection fraction (LVEF) and a resting HR C75 bpm, also in combination with beta-blocker therapy. According to very recent registry data, the prescription rates for ivabradine in patients with reduced LVEF in Europe are still low, while angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers are widely used [9] .
Thus, data analyzing the use of ivabradine in daily practice are still limited. Therefore, we conducted a prospective, non-interventional, open-label, multicenter study (INTENSIFY; PractIcal daily effectiveNess and TolEraNce of ivabradine in chronic SystolIc heart Failure in GermanY) to collect data on the use and tolerability of ivabradine in an ambulatory setting in patients suffering from CHF treated by cardiologists, specialized general practitioners (GPs), and internists. We focused on the effect of ivabradine on HR reduction, heart failure symptoms, and quality of life (QOL).
METHODS
Patients with chronic systolic heart failure fulfilling criteria for treatment with ivabradine according to the approved indication or
European guideline [7] recommendations (sinus rhythm, NYHA class II-IV, resting HR C70/75 bpm) were included in the study by treating physicians in an outpatient setting (cardiologists, specialized GPs, and internists).
There were 3 scheduled visits, one at baseline (visit 1), a control visit after 4 weeks (visit 2), and the final examination after 4 months (visit 3). A standardized case report form was used to record all data. To assess the overall response rate of patients to ivabradine, treatment response was defined as achieving an HR\70 bpm or an absolute reduction of at least 10 bpm at visit 3, reflecting the recommendations of the current European Society of Cardiology (ESC) heart failure guidelines [7] for treatment with ivabradine and also the inclusion criteria of the SHIFT trial (C70 bpm) [12] . 
RESULTS
In total, 1,956 patients with CHF were documented by 694 centers in Germany. The mean study duration was 126 ± 24.4 days. The mean age of the cohort was 67 ± 11.7 years, and 56.9% of the patients were male.
The CHF diagnosis had been known for more than 6 months in 85.4% of the population and for more than 3 months in 14.6%. The etiology of CHF was ischemic in 62.4% of patients, nonischemic in 31.7%, and both in 5.8%. Nearly all patients (97.9%) presented with at least one concomitant disease, most commonly hypertension (85.1%), hyperlipidemia (60.3%), diabetes mellitus (38.0%), and asthma/chronic obstructive pulmonary disease (27.0%; Table 1 ).
As concomitant medication, 77.8% of patients received beta-blockers (32.7% metoprolol, 27.7% bisoprolol, 8.5% nebivolol, and 6.6% carvedilol). 19.9% of patients received at least the beta-blocker target dose, 55.8% at least 50% but less than 100% of the target dose, and 24.3% less than 50% of target dose (Table 2 ). The mean daily dose was 103.7 mg for metoprolol, 6.2 mg for bisoprolol, 5.4 mg for nebivolol, and 27.7 mg for carvedilol (Table 3) . Apart from lower mean metoprolol dose in the low HR group, there were no relevant differences in average doses of beta-blockers between patients with low (\75 bpm), moderately elevated (75-84 bpm) and high baseline HR (C85 bpm). The proportion of patients receiving less than 50% of the betablocker target dose was higher and the proportion receiving 50-99% lower in the subgroup with low HR, compared to the subgroups with moderately elevated and high HR (Table 3 ). Other concomitant medications included ACE inhibitors or ARBs (83%), diuretics (61%), aldosterone antagonists (18%), cardiac glycosides (8%), aspirin (58%), and statins (56%).
Insufficient HR lowering with a beta-blocker was the most common reason for prescribing ivabradine, documented in 74.6% of patients, followed by decreased exercise capacity in 43.6% and intolerance to high doses of betablockers in 40.5%. 90.4% of patients started with 5 mg, 9.3% with 2.5 mg, and 0.2% with 7.5 mg twice daily. At visit 3, 44.1% of patients received 5 mg, 52.4% were treated with 7.5 mg, and 3.5% with 2.5 mg ivabradine twice daily.
The mean duration of treatment with ivabradine was 123.4 ± 28.1 days. In 4.4% of patients, the study drug was discontinued for different reasons (50.0% patient's request, 14.1% insufficient efficacy, 20.5% intolerance, 15.4% lack of compliance, and 29.5% other reasons).
The mean HR of patients was reduced by ivabradine from 85 ± 11.8 bpm at baseline to 72 ± 9.9 bpm after 1 month and 67 ± 8.9 bpm after 4 months at visit 3 ( Fig. 1 ). Relative HR (Fig. 2) . The change in NYHA class was comparable in all three subgroups defined by baseline HR.
At baseline, 26.6% of patients had an LVEF B35%. This proportion declined during the study to 17.4% at visit 3 ( Fig. 3 ). There were no relevant differences either in baseline LVEF or in LVEF changes between subgroups defined by baseline HR.
At the initial visit, 22.7% of all patients showed signs of decompensation (edema, dyspnea, etc.). This proportion had decreased to 5.4% at the final visit (Fig. 3) . The proportion of patients with signs of decompensation was slightly lower at all three visits in the subgroup with a baseline HR of\75 bpm compared with (Fig. 4) . Reductions in signs of decompensation and BNP values were observed in all baseline HR subgroups at the end of the study period. The mean value of the QOL EQ-5D sum score index was 0.64 ± 0.28 at baseline and had improved to 0.79 ± 0.21 at visit 3. A similar improvement was seen in the EQ-5D visual analog scale (Fig. 5) ,
with comparable results in all HR subgroups. Patients with missing values for heart rate are included in the ' 'total' ' column in case of existing documentation of beta-blocker dosing, though they are not considered in the stratified heart rate analysis Overall, 2.9% of patients treated with ivabradine reported at least one adverse event.
0.3% of patients died during the 4-month follow-up period, reflecting a low-risk CHF outpatient cohort. The most common adverse events were cardiac (1.4%), related to the nervous system (0.5%), or to the eye (0.5%).
Bradycardia was detected in 0.3% of patients (n = 5) in the whole study cohort and was more common in the group with baseline HR\75 bpm than in the two subgroups with higher baseline HRs (1.0% vs. 0% and 0.2%, respectively).
In the final examination, the physicians rated the effectiveness of ivabradine as very good in 54.9% of patients and good in 41.5%.
The proportion of patients for whom effectiveness was rated as very good was higher in the subgroup with a baseline HR of[85 bpm than in the 2 subgroups with lower HR (58.4% vs. 51.5% and 50.2%, respectively).
Tolerability was rated by the physicians as very good in 68.2% and good in 31% of patients. The proportion of patients with tolerability rated as very good was lower in the subgroup with baseline HR\75 bpm than in the other subgroups with higher baseline HRs (61.7% vs. Sargento et al. [14] , showing that a significant Fig. 4 Proportion of patients with BNP levels B400 or[400 pg/mL from baseline to study end (month 4). BNP brain natriuretic peptide Also, QOL of patients was significantly improved with ivabradine and combination treatment versus baseline, while no effect was shown for carvedilol monotherapy.
The hidden symptomatic ''benefit reserve'' in the INTENSIFY cohort before the start of ivabradine treatment could obviously not be targeted solely with beta-blockers, which most patients received. As CHF diagnosis was known for more than 6 months in 85.4% of patients, it is justified to consider that beta-blocker uptitration has been completed in that period of time. It should be noted that there was no intensification of beta-blocker treatment or other CHF therapy during the study period that could have contributed to the symptomatic improvement. In contrast, even a tendency to discontinuation or to reduction in existing beta-blocker therapy could be observed after 4 months. The results of our study emphasize that there was room for further symptomatic improvement in these patients, despite betablocker treatment in line with current guidelines the dosage of which can be considered to be optimized at study inclusion.
Interestingly, at baseline, patients with higher HRs tend to be treated with considerably higher mean doses of metoprolol, which was the most widely used beta-blocking agent in this patient cohort. There are other studies confirming that HR reduction is not consistently related to betablocker dose [16] . For example, Franke et al. [8] analyzed 443 CHF patients with an LVEF B35% and NYHA class II-IV. After careful up-titration of beta-blocker treatment, 29% of patients reached the recommended target dose and 69% at least half of it. Despite this optimized beta-blockade in clinical practice, 53% of patients remained on an HR C75 bpm [8] .
There is now also growing evidence from recent clinical studies [17, 18] and also metaanalyses of beta-blocker studies [19, 20] that treatment in CHF patients should not be strictly focused on achieving certain beta-blocker target dosages, which seem not to be related to clinical outcomes, but rather should concentrate on the cumulative HR reduction that can be achieved by different rate-reducing agents in the therapeutic regimen. The magnitude of HR reduction was closely correlated with prognosis in the abovementioned studies.
HR reduction by ivabradine also improved QOL considerably in the INTENSIFY study, as reflected by the observed increase in EQ-5D
parameters. This finding is also in line with a secondary analysis from the SHIFT trial, showing that HR reduction by ivabradine was associated with a significant increase in QOL [21] . There was clear relationship between the magnitude of HR reduction and improvement in QOL, and also an inverse relation between QOL measures and incidence of the primary composite end point of the trial. The QOL improvement in our study is of considerable clinical relevance. The result lies well within the range that can be achieved by percutaneous coronary intervention treatment in symptomatic patients with coronary artery disease (roughly 0.2 index points on the EQ-5D), which is an established treatment of proven efficacy in these patients [22] .
Ivabradine produced similar improvements in a large patient cohort with symptomatic coronary artery disease in clinical practice [23] .
For CHF patients on the other hand, an extensive meta-analysis failed to show a significant improvement in QOL for betablocker treatment, irrespective of proven mortality reduction [24] . These results are supported by a study by Riccioni et al. [25] and also a head-to-head comparison trial of ivabradine, carvedilol, or combination treatment [15] , demonstrating greater improvement in QOL with ivabradine alone or with combination therapy with carvedilol compared with carvedilol alone. In this headto-head study, Volterrani et al. [15] found no significant effect of carvedilol monotherapy on QOL after 3 months of treatment versus baseline. The positive effect of ivabradine on QOL of CHF patients also needs to be considered in the context that such data is, to our knowledge, largely missing for other heart failure standard medications (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists). No improvement in QOL could be demonstrated for beta-blockers, and only modest effects or delay of progressive worsening of QOL for ACE inhibitors [26] . No effect on symptom status or QOL measures was seen in a randomized trial with eplerenone compared with placebo in NYHA II/III CHF patients [27] .
Keeping in mind the growing relevance of QOL improvement as an important therapeutic goal in heart failure therapy, ivabradine seems to provide a specific additional benefit here compared with other prognostic standard medications.
Taken together, the results from INTENSIFY add to this evidence in demonstrating additional improvement in symptoms and in QOL in combination with standard beta-blocker therapy.
STUDY LIMITATIONS
An important limitation of this trial is its openlabel, observational, non-interventional design with no placebo group, which may lead to an overestimation of the treatment effects. On the other hand, the efficacy of ivabradine in combination with beta-blocker has been consistently proven in a large randomized clinical trial with CHF patients [12] . Moreover, the open study design allows evaluation of treatment effects under conditions of routine clinical practice, while in controlled studies strict inclusion criteria usually restrict access of broader patient populations with, for example, multiple comorbidities and risk factors.
Another limitation is the relatively short study duration of 4 months, which is nevertheless sufficient to evaluate symptom reduction and QOL in CHF patients, as already demonstrated in other studies [14, 15, 24] . The high resting HR at baseline can also lead to an overestimation of the treatment benefit, as the ivabradine effects are more pronounced in patients with a high HR, due to its usedependent mechanism of action. But with only slightly more than half of the patients being up-titrated to the recommended maintenance dose of ivabradine, treatment effects may also be underestimated.
Due to the non-interventional design, an underestimation of adverse events cannot be fully excluded, as they were not specifically looked for and were evaluated only in the form of an open interview at each visit. But taking into account favorable safety results from controlled clinical trials, ivabradine in combination with beta-blockers and other frequently prescribed drugs appears to be well tolerated in CHF patients [12, 15] .
CONCLUSION
In this prospective open-label study, ivabradine was effective in reducing HR and symptoms in CHF patients over a period of 4 months. There was a marked reduction in the proportion of 
